Russell Investments Group Ltd. Has $1.12 Million Holdings in Embecta Corp. (NASDAQ:EMBC)

Russell Investments Group Ltd. increased its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 151.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 54,371 shares of the company's stock after purchasing an additional 32,787 shares during the period. Russell Investments Group Ltd. owned about 0.09% of Embecta worth $1,123,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in shares of Embecta by 156.1% during the third quarter. Jane Street Group LLC now owns 176,487 shares of the company's stock worth $2,488,000 after purchasing an additional 107,567 shares during the period. Barclays PLC grew its position in Embecta by 41.1% in the third quarter. Barclays PLC now owns 97,930 shares of the company's stock worth $1,381,000 after acquiring an additional 28,523 shares in the last quarter. Geode Capital Management LLC grew its position in Embecta by 3.4% in the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock worth $19,564,000 after acquiring an additional 45,228 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Embecta during the 3rd quarter worth $217,000. Finally, Garden State Investment Advisory Services LLC bought a new position in shares of Embecta during the 3rd quarter valued at $438,000. Institutional investors and hedge funds own 93.83% of the company's stock.

Insider Buying and Selling

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the completion of the sale, the director now owns 36,133 shares in the company, valued at approximately $591,858.54. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.42% of the stock is currently owned by insiders.

Embecta Stock Performance

Shares of Embecta stock traded up $0.08 on Friday, reaching $11.83. The stock had a trading volume of 132,946 shares, compared to its average volume of 455,028. The business's 50-day moving average price is $12.77 and its two-hundred day moving average price is $15.82. The stock has a market cap of $687.73 million, a P/E ratio of 11.83, a price-to-earnings-growth ratio of 0.78 and a beta of 1.23. Embecta Corp. has a fifty-two week low of $10.00 and a fifty-two week high of $21.48.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. As a group, equities analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a $0.15 dividend. The ex-dividend date was Friday, February 28th. This represents a $0.60 annualized dividend and a dividend yield of 5.07%. Embecta's dividend payout ratio is 60.00%.

Analysts Set New Price Targets

Separately, Mizuho began coverage on shares of Embecta in a research report on Thursday, April 10th. They set a "neutral" rating and a $15.00 target price on the stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.